Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.12
Views: 8246

Dr Tony Mok - Chinese University of Hong Kong

Dr Tony Mok, professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, reported data at a press conference at ESMO 2012 in Vienna, from an exploratory study which suggests that EGFR mutations may help to achieve this goal in patients with lung cancer.


The analysis was conducted using tumour and/or plasma mutation data from 347 patients who took part in the MISSION trial. EGFR and KRAs mutations were detected in 26% and 20% patients, respectively, and were well balanced between treatment arms, the researchers report.


ecancerNews Coverage from ESMO 2012

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation